U.S. markets closed

argenx SE (ARGX.BR)

Brussels - Brussels Delayed Price. Currency in EUR
334.70+1.80 (+0.54%)
At close: 05:35PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close332.90
Bid0.00 x 0
Ask0.00 x 0
Day's Range332.40 - 337.00
52 Week Range250.70 - 405.50
Avg. Volume49,267
Market Cap18.599B
Beta (5Y Monthly)0.48
PE Ratio (TTM)N/A
EPS (TTM)-12.08
Earnings DateMay 04, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est441.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ARGX.BR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • TipRanks

      TipRanks ‘Perfect 10’ List: 2 Top Stocks That Analysts Are Placing Their Bets On

      The last two weeks have seen the markets take a rollercoaster ride, that’s for sure. The sudden insolvency and failure of Silicon Valley Bank, and the Federal closures of Signature and Silvergate banks, have triggered worries of an old-fashioned bank run. An announcement by Credit Suisse, that it was having difficulty accessing capital, fed fears that even the major banking names would not be immune to contagion. President Biden and Treasury Secretary Yellen have made it clear that account holde

    • GlobeNewswire

      argenx Announces Annual General Meeting of Shareholders on May 2, 2023

      March 17, 2023 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that an Annual General Meeting of shareholders will be held at 12:00 PM CET on Tuesday, May 2, 2023 at Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands. The shareholders and all other persons with meeting rights are invited to attend the Annual Genera

    • GlobeNewswire

      argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis

      VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in the UK for the treatment of adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patients treated with placebo (n=19/64) (p<0.0001) during the first treatment cycle in the Phase 3 ADAPT